Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR ...

But in 2004, a groundbreaking new treatment called anti-VEGF—including drugs such as Lucentis, Eylea, and Avastin—became available. These drugs work to stop the blood vessels from growing ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

“Based on these new data, aflibercept 8 mg may offer the potential to halve the number of injections needed, as compared to standard-of-care aflibercept 2 mg and other anti-VEGF therapies.” ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Regeneron offered a price concession that lowered Eylea’s selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications ...